Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
Brachytherapy proves beneficial regardless of treatment duration
HONOLULU – The median overall survival was better among patients who received brachytherapy for 8 weeks or longer...
News
Oral triplet deemed effective in relapsed/refractory myeloma
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma....
News
Guadecitabine may be option for certain MDS/AML patients
Patients with few or no somatic mutations were more likely to respond to guadecitabine in the phase 2 trial.
News
Early career researchers win funding
Seven researchers won funding from the Parker Institute for Cancer Immunotherapy, and another researcher received a grant from the Ovarian Cancer...
News
Analysis suggests ‘Burkitt-like lymphoma’ is a misnomer
Burkitt-like lymphoma with 11q aberration appears more closely related to other lymphomas than to typical Burkitt lymphoma.
News
KD025 produces durable responses in patients with cGVHD
HOUSTON – Many responses have lasted 20 weeks or more, and durability data are still maturing.
News
Ixazomib targets treatment failure in chronic GVHD
HOUSTON – Most patients in the phase 2 trial had severe chronic graft-versus-host disease and most had received three or more prior lines of...
News
Post-HCT azithromycin doesn’t increase relapse risk, study suggests
HOUSTON – A prior study indicated that pretransplant azithromycin increases the risk of relapse.
News
Gene expression signature reveals high-grade GCB DLBCL
Patients with this signature had inferior survival outcomes.
News
Priority review granted to lenalidomide for FL, MZL
Celgene is seeking approval for lenalidomide in combination with rituximab to treat previously treated follicular lymphoma or marginal zone...
News
FDA approves subcutaneous trastuzumab for HER2-positive breast cancers
The subcutaneous formulation of trastuzumab can be administered over approximately 2-5 minutes.
News
Cancer researchers awarded for breakthroughs
Winners of the Sjöberg Prize, the Szent-Györgyi Prize, and the Dr. Nathan Davis Award for Outstanding Government Service.
News
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News
Regimen shows promise as salvage for classical HL
Most patients studied responded to the regimen.
News
FDA grants priority review to polatuzumab vedotin for DLBCL
The FDA is expected to make a decision on the drug by Aug. 19, 2019.